DXVX

180400KOSDAQ

42.0 / 100

Reference Date: 2026-10-23

Financial Score11.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 15.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DXVX is a biopharmaceutical company specializing in medical diagnostics, healthcare, and drug development, expanding globally through the 2022 acquisition of Hanbio Pharm and the 2023 establishment of a Chinese subsidiary. In medical diagnostics, it leverages NGS and AI-based platforms with GMP-certified facilities, while its drug development focuses on oncology therapies through partnerships with Stanford University and the acquisition of Evexis Gen. The company plans to mitigate financial risks by licensing technologies to major pharmaceutical firms.

Number of Employees

62people

Average Salary

107.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.05Industry Average 1.201.0Point

1.7x industry avg (risky)

ROE

-52.77Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

39.00Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼20.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼45.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -123.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 1,998Won52-week high 5,11052-week low 1,653

1-month return1.0Point

1m -14.98% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-12
Neutral대표이사변경2026-10-08
Neutral임시주주총회결과2026-10-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-01
Neutral주식등의대량보유상황보고서(일반)2026-09-28